Indirect trans-arterial thrombolysis versus Anticoagulation alone for therapy of portal and/or splanchnic thromboses - a retrospective controlled trial

Indirect trans-arterial thrombolysis versus Anticoagulation alone for therapy of portal and/or splanchnic thromboses - a retrospective controlled trial - Indirect Lysis portal vein

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035727

Enrollment

Registered

2026-06-11

Start date

2025-04-15

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I81

Interventions

Group 1: Thrombolysis via A. mesenterica superior Group 2: oral or i.v. anticoagulation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Extended portal and/or splanchnic thrombosis Indirect thrombolysis or anticoagulation alone

Exclusion criteria

Exclusion criteria: Liver cirrhosis tumor thrombus

Design outcomes

Primary

Measure	Time frame
Thrombus volume after therapy/at discharge	—

Secondary

Measure	Time frame
Bleeding complications	—

Countries

Germany

Contacts

Public ContactKatharina Vogt

Uniklinik Freiburg, Klinik für Diagnostische und Interventionelle Radiologie

katharina.vogt@uniklinik-freiburg.de+4976127038582

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026